These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16513102)
1. A novel method to quantify in vivo transferrin glycation: applications in diabetes mellitus. Van Campenhout A; Van Campenhout C; Olyslager YS; Van Damme O; Lagrou AR; Manuel-y-Keenoy B Clin Chim Acta; 2006 Aug; 370(1-2):115-23. PubMed ID: 16513102 [TBL] [Abstract][Full Text] [Related]
2. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. Van Campenhout A; Van Campenhout C; Lagrou A; Manuel-y-Keenoy B Biometals; 2008 Apr; 21(2):159-70. PubMed ID: 17585373 [TBL] [Abstract][Full Text] [Related]
3. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Van Campenhout A; Van Campenhout C; Lagrou AR; Moorkens G; De Block C; Manuel-y-Keenoy B Free Radic Biol Med; 2006 May; 40(10):1749-55. PubMed ID: 16678014 [TBL] [Abstract][Full Text] [Related]
4. Impact of diabetes mellitus on the relationships between iron-, inflammatory- and oxidative stress status. Van Campenhout A; Van Campenhout C; Lagrou AR; Abrams P; Moorkens G; Van Gaal L; Manuel-y-Keenoy B Diabetes Metab Res Rev; 2006; 22(6):444-54. PubMed ID: 16506275 [TBL] [Abstract][Full Text] [Related]
5. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Lee DH; Liu DY; Jacobs DR; Shin HR; Song K; Lee IK; Kim B; Hider RC Diabetes Care; 2006 May; 29(5):1090-5. PubMed ID: 16644642 [TBL] [Abstract][Full Text] [Related]
7. Elevated iron indices in patients with diabetes. Thomas MC; MacIsaac RJ; Tsalamandris C; Jerums G Diabet Med; 2004 Jul; 21(7):798-802. PubMed ID: 15209778 [TBL] [Abstract][Full Text] [Related]
8. [Concentrations of serum iron and transferrin in children with nephrotic syndrome]. Lu HZ; Yuan YS; Zhang WM; Liu D; Kuang HY Zhongguo Dang Dai Er Ke Za Zhi; 2006 Dec; 8(6):467-9. PubMed ID: 17178036 [TBL] [Abstract][Full Text] [Related]
9. Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. van Campenhout A; van Campenhout CM; Lagrou AR; Manuel-y-Keenoy B Free Radic Res; 2003 Oct; 37(10):1069-77. PubMed ID: 14703796 [TBL] [Abstract][Full Text] [Related]
10. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Lodovici M; Giovannelli L; Pitozzi V; Bigagli E; Bardini G; Rotella CM Mutat Res; 2008 Feb; 638(1-2):98-102. PubMed ID: 17964614 [TBL] [Abstract][Full Text] [Related]
11. [Anemia and iron metabolism in patients with type-2 diabetes mellitus]. Kovács F; Szakál I; Révész K; Lévai A; Dobos A Orv Hetil; 2006 Feb; 147(8):345-9. PubMed ID: 16579333 [TBL] [Abstract][Full Text] [Related]
12. Action of pelargonidin on hyperglycemia and oxidative damage in diabetic rats: implication for glycation-induced hemoglobin modification. Roy M; Sen S; Chakraborti AS Life Sci; 2008 May; 82(21-22):1102-10. PubMed ID: 18440560 [TBL] [Abstract][Full Text] [Related]
13. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Pieters M; Covic N; Loots du T; van der Westhuizen FH; van Zyl DG; Rheeder P; Jerling JC; Weisel JW Thromb Haemost; 2006 Nov; 96(5):623-9. PubMed ID: 17080220 [TBL] [Abstract][Full Text] [Related]
14. [The comparison of diagnostic usefulness of transferrin determination by immunological and chemical method in iron deficiency anemia]. Krawiec A; Cylwik B; Chrostek L; Szmitkowski M Pol Merkur Lekarski; 2007 Mar; 22(129):173-6. PubMed ID: 17682669 [TBL] [Abstract][Full Text] [Related]
15. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Rajasekar P; Anuradha CV Acta Diabetol; 2007 Jun; 44(2):83-90. PubMed ID: 17530472 [TBL] [Abstract][Full Text] [Related]
16. Factors accounting for high ferritin levels in obesity. Lecube A; Hernández C; Pelegrí D; Simó R Int J Obes (Lond); 2008 Nov; 32(11):1665-9. PubMed ID: 18779821 [TBL] [Abstract][Full Text] [Related]
17. Preferential recognition of Amadori-rich lysine residues by serum antibodies in diabetes mellitus: role of protein glycation in the disease process. Ansari NA; Moinuddin ; Alam K; Ali A Hum Immunol; 2009 Jun; 70(6):417-24. PubMed ID: 19332092 [TBL] [Abstract][Full Text] [Related]
18. Advanced glycosylated end products-mediated activation of polymorphonuclear neutrophils in diabetes mellitus and associated oxidative stress. Gupta A; Tripathi AK; Tripathi RL; Madhu SV; Banerjee BD Indian J Biochem Biophys; 2007 Oct; 44(5):373-8. PubMed ID: 18341213 [TBL] [Abstract][Full Text] [Related]
19. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of iron status in lemurs by analysis of serum iron and ferritin concentrations, total iron-binding capacity, and transferrin saturation. Williams CV; Junge RE; Stalis IH J Am Vet Med Assoc; 2008 Feb; 232(4):578-85. PubMed ID: 18279098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]